An executive order can speed attention, but that does not equal FDA approval.

Ibogaine is getting attention, but there are still concerns about safety.

Access and cost of potential psychedelic treatments still remain big questions.

Psychedelic medicine has been building momentum for years, but the new executive order signed on April 18, 2026, has pushed the conversation into much more public territory. The order, titled Accelerating Medical Treatments for Serious Mental Illness, directs federal agencies to move more quickly on research, review, and access pathways for investigational psychedelic treatments. That kind of headline naturally creates excitement, but also should be approached with caution and likely some limitations on what it can and cannot do for treatment options.

The first thing worth saying clearly is this: An executive order is not Food and Drug Administration (FDA) approval. It does not mean psychedelic medications are suddenly available in routine psychiatric care, and it does not mean the evidence questions have been settled. What it does mean is that the federal government is signaling unusual interest in helping parts of the development and regulatory process move faster.

For patients and families, that distinction matters. In psychiatry, a treatment can be promising long before it is practical, scalable, or appropriate for widespread use. Many people living with depression, posttraumatic stress disorder (PTSD), addiction, and other difficult-to-treat conditions are understandably hungry for better options. That longing is real. But hope and readiness are not the same thing.

What this order does not mean

It helps to be clear what the executive order does not do:

It does not make psychedelic drugs FDA-approved.

It does not make psychedelic drugs FDA-approved.

It does not make these treatments widely available tomorrow.

It does not make these treatments widely available tomorrow.

It does not waive well-designed clinical trials to ensure treatment is safe and effective.

It does not waive well-designed clinical trials to ensure treatment is safe and effective.

It does not settle ongoing questions about safety, effectiveness, or who is an appropriate candidate.

It does not settle ongoing questions about safety, effectiveness, or who is an appropriate candidate.

It does not solve the practical challenges of delivering these treatments in the real world.

It does not solve the practical challenges of delivering these treatments in the real world.

Why ibogaine stands out

One of the more surprising parts of this executive order is how directly it references ibogaine. That stood out to me right away; as someone who monitors drug development closely, I was surprised by the emphasis that was made on ibogaine due to the fact that it is much further behind in clinical trials and potential to be a commercialized product available to the public. While there are various trials investigating the use of ibogaine for various conditions such as PTSD, traumatic brain injuries, depression, and addiction treatment, there are few in FDA registrational trials. One notable trial is in Phase 1 for oral noribogaine, a psychoactive metabolite of ibogaine, as "DMX-1001" for alcohol use disorder and substance use disorders. Previous safety concerns—short-term effects during treatment as well as longer-term effects—include abnormal heart rhythms, in particular.

Not all psychedelic treatments are equally far along

One problem with the public conversation is that people often talk about “psychedelics” as though this is one uniform category moving at the same speed. It is not. These are different compounds with different risk profiles, different trial programs, and different levels of evidence. And right now, some programs are further along than ibogaine. Currently, from available data today, the front-runners with the clinical trials furthest along are psilocybin and LSD. Both investigational treatments have been designated "breakthrough status," which allows pharmaceutical companies and the FDA to work in tandem to help speed up the development and review of drugs intended to treat serious or life-threatening conditions and demonstrate substantial evidence supporting benefits over available therapies. It is important to note that "breakthrough therapy designation" does not guarantee approval, and full clinical trials are required to demonstrate that the investigational treatments are both safe and effective. Current late-stage development include:

COMP360 psilocybin has reported positive Phase 3 data in treatment-resistant depression.

COMP360 psilocybin has reported positive Phase 3 data in treatment-resistant depression.

MM120 orally disintegrating tablet, an LSD-based treatment, is in Phase 3 development for generalized anxiety disorder and major depressive disorder.

MM120 orally disintegrating tablet, an LSD-based treatment, is in Phase 3 development for generalized anxiety disorder and major depressive disorder.

Both of these investigational treatments may file formally with the FDA for the New Drug Application process, which is the formal submission to the FDA that could potentially lead to approval.

Policy and funding matter—but infrastructure matters, too

It is also worth paying attention to the money. The White House fact sheet says the administration will direct at least $50 million in existing Department of Health and Human Services (HHS) funds through ARPA-H to support state collaboration and related programs. That is not trivial. But funding alone does not answer the bigger implementation questions. A treatment is not truly accessible just because it exists. It has to be deliverable. Even if one or more psychedelic treatments eventually gain approval, approval is only part of the story. The other part is structure. In the COMP360 model, the psilocybin session itself has been described as lasting about 6 to 8 hours, with therapist support throughout. That is a very different model than a standard medication visit, and even longer than the in-clinic observation period many clinicians are familiar with for esketamine.

If these treatments move closer to routine care, patients and families will still have to navigate questions like:

What will treatment actually require in terms of time, travel, and support?

Who will provide transportation?

Which clinics will have trained staff and enough space?

How will insurers handle reimbursement for long, supervised sessions?

Will access be limited to major cities or specialty centers?

What barriers will remain for patients in rural, lower-income, or underserved communities?

As these treatments may move closer to FDA approval and be available as medicine, health care providers, patients, and families will need to navigate practical questions on how to deliver these new therapies in clinical practice. As mentioned in the discussion with President Trump during the executive order signing session, these treatments are not expected to be given at home and will need to be given in health care facilities with proper supervision during administration. This may require consideration of what offices and facilities have the ability out of the gate to navigate the demands that new treatments have on staffing and infrastructure.

This executive order matters. It reflects a real shift in federal tone and gives more visibility to a field that has often lived at the edges of medicine and advocacy. But it does not eliminate the need for careful trials, honest discussions about risk, or the practical realities of how these treatments would actually be delivered. That is the part I hope patients and families keep in mind. This order may accelerate momentum and discussion, but it does not replace thorough clinical trials and thoughtful discussion amongst deploying those treatments, and it certainly does not answer all of the questions that come after a promising treatment becomes a real-world treatment. I am very hopeful these investigational treatments will provide a solution for many suffering from undertreated and inadequately treated mental health conditions and pave the way for a new style of treatment that may not require daily oral medication treatment or multiple sessions over many weeks.

The White House. (2026, April 18th). Accelerating medical treatments for serious mental illness. White House. Available: https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-me…

Esperança MP, Gomes NGM, Campos MG. Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders-A Scoping Review. Molecules. 2026 Feb 4;31(3):545.

Demurx, Inc. (2025, January 27). DemeRx announces successful completion of multiple ascending dose clinical trial of DMX-1001 for the treatment of alcohol use disorder (AUD). Available: https://www.demerx.com/demerx-announces-successful-completion-of-multip…

Definium Therapeutics, Inc. (2026). Research & Development Pipeline. Definium Therapeutics. Available: https://definiumtx.com/#pipeline

Compass Pathways plc. (2026). Pipeline overview. https://compasspathways.com/our-work/pipeline-overview/

There was a problem adding your email address. Please try again.

By submitting your information you agree to the Psychology Today Terms & Conditions and Privacy Policy

© Psychology Today